Skip Navigation



Annals of Oncology Advance Access published online on May 7, 2008
Annals of Oncology, doi:10.1093/annonc/mdn173
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/9/1650    most recent
mdn173v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Knab, B. R.
Right arrow Articles by Vokes, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knab, B. R.
Right arrow Articles by Vokes, E. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma

B. R. Knab1, J. K. Salama1,2,*, A. Solanki3, K. M. Stenson4, E. E. Cohen2,5, M. E. Witt1, D. J. Haraf1,2 and E. E. Vokes1,2,5

1 Department of Radiation and Cellular Oncology, Chicago
2 Cancer Research Center
3 Pritzker School of Medicine, University of Chicago, Chicago
4 Section of Otolaryngology/Head and Neck Surgery, University of Chicago, Chicago
5 Section of Hematology/Oncology, University of Chicago, Chicago, USA

* Correspondence to: Dr J. K. Salama, Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue, MC 9006, Chicago, IL 60637, USA. Tel: +1-773-702-6870; Fax: +1-773-834-7340; E-mail: jsalama{at}radonc.uchicago.edu

Background: Randomized trials established chemoradiotherapy as standard treatment for advanced laryngeal cancer. Patients with large-volume T4 disease (LVT4) were excluded from these trials. The purpose of this study was to report T4 laryngeal cancer patient outcome, including those with LVT4 disease, treated with chemoradiotherapy.

Patients and methods: This study is a retrospective subset analysis of 32 patients with T4 laryngeal carcinoma including LVT4 tumors treated on three consecutive protocols investigating paclitaxel (Taxol), 5-fluorouracil, hydroxyurea, and 1.5-Gy twice daily (BID) radiotherapy (TFHX).

Results: Median follow-up is 43 months. Four-year locoregional control (LRC), disease-free survival (DFS), overall survival (OS), and laryngectomy-free survival (LFS) was 71%, 67%, 53%, and 86%, respectively. Four patients required laryngectomy for recurrent or persistent disease. Of disease-free patients with ≥1 year follow-up, 90% demonstrated normal or understandable speech. None required laryngectomy for complications. Among LVT4 patients, 4-year LRC, DFS, OS, and LFS was 71%, 65%, 56%, and 81%, respectively. Induction chemotherapy improved 4-year LRC (90% versus 46%, P = 0.03) and DFS (84% versus 42%, P = 0.03).

Conclusions: Promising control and functional outcomes are achieved with TFHX for T4 laryngeal patients. LVT4 disease had outcomes similar to patients with less advanced disease treated on Radiation Therapy Oncology Group 91-11. Induction chemotherapy improved outcomes, warranting further investigation.

chemoradiotherapy, head and neck cancer, induction chemotherapy, larynx therapy, organ preservation, T4 laryngeal cancer

Received for publication November 17, 2007. Revision received January 29, 2008. Accepted for publication March 25, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.